Experimental Alzheimer's drug slows cognitive declines in large trial, drugmaker Eli Lilly says | CNN

Wednesday. Based on the results, in people with early symptomatic Alzheimer’s disease, Lilly said it plans to file for approval from the US Food and Drug Administration by the end of June. The medicine, donanemab, works by removing plaque buildups in the brain known as amyloid that are a hallmark of Alzheimer’s disease.

Skovronsky, who noted he’s been working in the field of Alzheimer’s for 25 years, said the new class of medicines is different because of “the amount of amyloid they can clear and how quickly they can clear it.” The medicine is given by infusion once a month. Donanemab clears amyloid so effectively, the company says, that a majority of patients in the trial – 52% – were able to stop taking the medicine by one year, and 72% were able to do so by a year and a half.

Law Law Latest News, Law Law Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Eli Lilly's Alzheimer's drug donanemab slows cognitive decline: trialAn experimental drug just showed it can help slow Alzheimer's, offering new hope for patients and a major boost to pharma giant Eli Lilly
Source: BusinessInsider - 🏆 729. / 51 Read more »

Eli Lilly Alzheimer’s treatment donanemab slowed disease progression in clinical trialDonanemab, a monthly antibody infusion made by pharmaceutical company Eli Lilly, also significantly reduced brain plaque associated with Alzheimer's disease.
Source: CNBC - 🏆 12. / 72 Read more »

Eli Lilly's diabetes drug could revolutionize the US weight loss marketEli Lilly’s diabetes drug delivers promising results in a recent clinical trial. The company hopes it will be added to the U.S. weight loss market soon.
Source: IntEngineering - 🏆 287. / 63 Read more »